Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Brian P, Monahan"'
Publikováno v:
Case Reports in Oncology, Vol 2, Iss 1, Pp 44-52 (2009)
Hidradenocarcinomas are rare, aggressive adnexal tumors of sweat gland origin that demonstrate a high potential for local recurrence, metastasis and poor outcome. These neoplasms can derive from preexisting clear cell hidradenomas, but more commonly
Externí odkaz:
https://doaj.org/article/575f5863f13641febda400789ebbc00f
Autor:
Brian P. Monahan, CelesteAnn T. Bremer
Publikováno v:
Current Gastroenterology Reports. 8:333-341
Neutropenic enterocolitis (NE) must be recognized in patients with fever, neutropenia, and abdominal pain. Classically, NE has been described in patients with hematologic malignancies treated with intensive chemotherapy. Current interest in NE has in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::674271d5b707ce403d4d426a1b38298b
https://doi.org/10.1007/s11894-006-0055-z
https://doi.org/10.1007/s11894-006-0055-z
Autor:
Dat Nguyen, Barbara Schuler, Nancy Harold, Geraldine Morrison, Xaiodu Guo, Maurice A. Wright, Mary G. Quinn, Jorge P. Leguizamo, Janet Pang, Eva Szabo, Gregory D. Leonard, M. Wasif Saif, Suzanne Fioravanti, Brian P. Monahan, Jon L. Hopkins, Pengxin Lin, Jean L. Grem
Publikováno v:
Clinical Cancer Research. 11:4144-4150
Purpose: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions. Experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::315c80d9fa45b860a95addad65a8f657
https://doi.org/10.1158/1078-0432.ccr-04-2439
https://doi.org/10.1158/1078-0432.ccr-04-2439
Publikováno v:
Integrative Cancer Therapies. 2:345-352
Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to conventional cancer therapies for more than 80years. Preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819d058d4fca32fb505198a5653bf94d
https://doi.org/10.1177/1534735403259061
https://doi.org/10.1177/1534735403259061
Autor:
Chris H. Takimoto, Dat Nguyen, Alice P. Chen, J. Michael Hamilton, Brian P. Monahan, Janet Pang, Mary G. Quinn, Yan Xu, Jean L. Grem, Anthony Rowedder, Bruce Keith, Nancy Harold, Geraldine Morrison
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:487-496
Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial.Gemcitabine alone was given in cycle 1 as a 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332cce0c9225697893274395cf2a66ee
https://doi.org/10.1007/s00280-003-0698-5
https://doi.org/10.1007/s00280-003-0698-5
Autor:
Martin C. Graham, Sunil Sharma, Jean L. Grem, Denis Greenslade, Ronald Knight, Graham F. Lockwood, Percy Ivy, Scot C. Remick, Andrew Goetz, Rebecca Thomas, James H. Doroshow, Chris H. Takimoto, Barbara Schuler, Brian P. Monahan, A. Hamilton, William Dahut, Merrill J. Egorin, Daniel Mulkerin, Sridhar Mani, Ramesh K. Ramanathan
Publikováno v:
Journal of Clinical Oncology. 21:2664-2672
Purpose: This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32985e08c705746249f06525d3581ea0
https://doi.org/10.1200/jco.2003.11.015
https://doi.org/10.1200/jco.2003.11.015
Autor:
Frank M. Balis, W. Corse, Chris H. Takimoto, David J. Liewehr, Mary Flanagan Quinn, Jean L. Grem, Robert F. Murphy, J M Hamilton, Carmen J. Allegra, Brian P. Monahan, Nancy Harold, Alice P. Chen, Janet Pang, Seth M. Steinberg, R. Lush, Abdel Salam Attia Ismail
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:117-125
Purpose: Clinical toxicity associated with 5-fluorouracil (5-FU) is related to the area under the plasma concentration-time curve (AUC). Recently, short-term infusions of 5-FU given over 30 or 60 min have been substituted for conventional "bolus" 5-F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f95c78225c9ae02d426e76afd3b2de8e
https://doi.org/10.1007/s002800000189
https://doi.org/10.1007/s002800000189
Autor:
Jamie M. Stagl, Timothy S. Sannes, Brian P. Monahan, Sandra M. Swain, Jean L. Grem, Dawn B. Wallerstedt, Laura Lee Johnson, Marc R. Blackman, Patrick J. Mansky
Publikováno v:
Evidence-Based Complementary and Alternative Medicine, Vol 2013 (2013)
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-based Complementary and Alternative Medicine : eCAM
Purpose.European Mistletoe (Viscum albumL.) extracts (mistletoe) are commonly used for cancer treatment in Europe. This phase I study of gemcitabine (GEM) and mistletoe in advanced solid cancers (ASC) evaluated: (1) safety, toxicity, and maximum tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfd8bc212554b6cd6039ea5fb7b86571
https://doaj.org/article/a926a66031a244279ddf5f6cead27f7c
https://doaj.org/article/a926a66031a244279ddf5f6cead27f7c
Autor:
Brian P. Monahan, Minocher Battiwalla, Jean L. Grem, John B Stockle, Gregory D. Leonard, Robert A Harris
Publikováno v:
The Lancet. Oncology. 4(6)
THE LANCET Oncology Vol 4 June 2003 http://oncology.thelancet.com 358 68 Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003; 63: 1114–21. 69 Wijermans PW, Krulder JW, Huijgens PC, e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472010620339c7b952ad02bfed91b824
https://pubmed.ncbi.nlm.nih.gov/12788408
https://pubmed.ncbi.nlm.nih.gov/12788408
Autor:
Jean L, Grem, Nancy, Harold, Bruce, Keith, Alice P, Chen, Viven, Kao, Chris H, Takimoto, J Michael, Hamilton, Janet, Pang, Marie, Pace, Gada B, Jasser, Mary G, Quinn, Brian P, Monahan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(7)
Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases I and II through a mechanism distinct from other topoisomerase poisons. PZA shows schedule-independent cytotoxicity against tumor cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3624f1b22b5c34db1a50c4e91288092f
https://pubmed.ncbi.nlm.nih.gov/12114415
https://pubmed.ncbi.nlm.nih.gov/12114415